KDL Biotech Ltd - KDL BIOTECH Share Price

Sector: Pharmaceuticals | ISIN: INE746A01010
₹ 2.10 (-4.55%) icon5 Dec, 2013, 12:00:00 AM

KDL Biotech Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 12/5/2013 12:00:00 AM

    ₹ 2.1 -0.10 -4.55
  • Open
  • ₹ 2.1
  • Prev. Close
  • ₹ 2.2
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 2.1
  • Day's Low
  • ₹ 2.1
  • 52 Week's High
  • ₹ 0
  • 52 Week's Low
  • ₹ 0
  • Book Value
  • ₹ -35.74
  • Face Value
  • ₹ 10
  • Mkt Cap (₹ Cr.)
  • 5.05
  • P/E
  • 0
  • EPS
  • 0
  • Divi. Yield
  • 0

KDL Biotech Ltd Corporate Actions

No Record Found


KDL Biotech Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

KDL Biotech Ltd SHAREHOLDING SNAPSHOT
20 April , 2024 | 07:40 AM

PROMOTER - TOTAL68.86%

Indian: 45.39%

Foreign: 23.4657%

NON-PROMOTER - TOTAL 31.14%

Institutions: 2.47%

Non-Institutions: 28.68%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

KDL Biotech Ltd FINANCIALS

No Data Available To Display Chart

KDL Biotech Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT KDL Biotech Ltd

  • Nalin Bamzai
  • Managing Director
  • Rajesh Agrawal
  • Director (Technical)
  • Sanjay Sinha
  • Director
  • Yogendra Kumar Chauhan
  • Director
  • Manish Bhojwani
  • Company Secretary
  • Avantika Varma
  • Additional Director

Summary

Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. The company has used research-based technology to contribute towards total health-care. From diagnostics to treatment, speciality bulks to finished dosage forms, bio-technology to sophisticated and medical electronic equipments maintaining quality on par with the best in the world, and thereby vying for brand equity in the global context.The companys major foray into the business of biotechnology based products its name is changed from Kopran Drugs to KDL Biotech (KDL).The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 TPA. Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Its is growing with a vision to focus on Brand Equity Development, Research for New Chemical Entities and globalise its operations thus making KDL a truly International Pharmaceutical... Read More


Reports by KDL Biotech Ltd


Reports by KDL Biotech Ltd

Company FAQ

No Record Found